Page results
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Our outpatient clinics will remain predominantly virtual throughout the COVID-19 pandemic. Please continue to refer via the NHS e-referral service.
File results
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients
-
FOI/2022/0193 - Drug treatment for breast cancer